Bender Robert & Associates Sells 427 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bender Robert & Associates cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 88,904 shares of the medical equipment provider’s stock after selling 427 shares during the period. Intuitive Surgical comprises approximately 7.6% of Bender Robert & Associates’ portfolio, making the stock its 3rd largest holding. Bender Robert & Associates’ holdings in Intuitive Surgical were worth $29,993,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in ISRG. Calamos Advisors LLC increased its holdings in Intuitive Surgical by 34.0% in the fourth quarter. Calamos Advisors LLC now owns 123,108 shares of the medical equipment provider’s stock valued at $41,532,000 after buying an additional 31,249 shares during the last quarter. AIA Group Ltd boosted its position in shares of Intuitive Surgical by 19.4% during the 4th quarter. AIA Group Ltd now owns 12,999 shares of the medical equipment provider’s stock worth $4,385,000 after acquiring an additional 2,108 shares in the last quarter. SFE Investment Counsel increased its holdings in shares of Intuitive Surgical by 6.2% in the 4th quarter. SFE Investment Counsel now owns 1,412 shares of the medical equipment provider’s stock valued at $476,000 after acquiring an additional 83 shares during the last quarter. Oliver Lagore Vanvalin Investment Group raised its position in shares of Intuitive Surgical by 71.1% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 3,694 shares of the medical equipment provider’s stock worth $1,246,000 after acquiring an additional 1,535 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Intuitive Surgical by 54.9% during the fourth quarter. Federated Hermes Inc. now owns 242,094 shares of the medical equipment provider’s stock worth $81,673,000 after purchasing an additional 85,843 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock valued at $95,927,097 over the last 90 days. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Down 0.4 %

Shares of ISRG traded down $1.54 during midday trading on Thursday, hitting $372.63. The company had a trading volume of 2,287,472 shares, compared to its average volume of 1,644,605. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76. The company’s 50 day moving average price is $387.56 and its 200 day moving average price is $342.39. The stock has a market cap of $132.08 billion, a price-to-earnings ratio of 74.39, a PEG ratio of 5.88 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the business posted $1.00 EPS. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. Equities analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ISRG. Raymond James upped their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Stifel Nicolaus raised their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Citigroup boosted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Barclays raised their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Finally, Royal Bank of Canada boosted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average price target of $375.70.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.